Shenzhen Congmingmu Announces a ￥10M Strategic Investment Round

According to VCBeat, recently, Shenzhen Congmingmu Intelligent Technology Co., Ltd. ("Shenzhen Congmingmu") has completed a ￥10 million strategic financing, with participation from Ovctek China (stock code: 300595.SZ), a listed company in the field of ophthalmology, and Shenzhen Langke Investment. WinX Capital acted as sole financial advisor and long-term capital advisor.

Founded in 2017 with the mission of helping more people solve their eye health problems through innovation, Shenzhen Congmingmu is positioned as an expert in the intelligent management of eye health. The company is committed to developing smart eye care products.

In the past decade, the development of electronic technology, the popularization of smartphones/tablets and the outbreak of mobile applications have led to a rapid increase in the number of patients with eye health problems around the world. According to the latest data, the number of patients with myopia in the world is growing swiftly, which is expected to reach 2.62 billion by 2020, accounting for more than 1/3 of the global population. By 2050, the global myopia rate will reach 50 percent.

For such a situation, Liu Cheng, the founder of Shenzhen Congmingmu, said, "Facing the trend of the new era, eye care devices and the application scenarios have changed suddenly. The traditional eye care system is in urgent need of transformation to an intelligent eye care system. Our ultimate goal is that every electronic product around users will be connected to our software-controlled eye health device. We can provide the hardware-oriented service based on the Internet built for eye care management.”

The founding team of Shenzhen Congmingmu consists of experts in ophthalmology and executives of smart hardware R&D in healthcare from Huawei, with the professional background of multiple disciplines such as materials, optics, mechanics, intelligent algorithms and clinical medicine. At present, the company has two brands, "Congmingmu" for the prevention and control of myopia in teenagers, and "Yanmu" for the protection of eyes in all ages.

Founded in 2000 by Dr. Tao Yuequn, Ovctek China is a high-tech enterprise specializing in developing technologies and services of prevention and control for eye health and myopia. Its business covers ophthalmology, and optometry medical devices (products) and medical services.

Founded in December 2014 by angel investor Xiaohua Cheng, Langke Investment is a subsidiary of Langke Technology, focusing on investments in the early stage.